News

This paper describes how we are reviewing results and data from advanced prostate cancer trials in new and different ways to find out quickly which treatments are best and for which men.

 

Our latest STOPCAP systematic review and meta-analysis, recently published in European Urology, has concluded that prostate radiotherapy should be considered for men with low metastatic burden, hormone sensitive prostate cancer (mHSPC).

We are looking for a Medical Statistician to play a key role in the design, conduct and analysis of systematic reviews and meta-analyses of both aggregate data and individual participant data (IPD), to guide clinical practice and new trial design, and in related methodological projects...

Our first meeting to launch the STOPCAP M1 programme was held in Munich, Germany on Saturday 20th October 2018.

Trial investigators and other collaborators were invited to attend and we would like to thank all those who came along.

Slides presented on the day are available in the full article ...

We would like to welcome trial investigators with trials with the scope of the STOPCAP M1 programme to a meeting during ESMO 2018. Progress, plans and results will be presented and discussed.